The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients
NCT ID: NCT07244770
Last Updated: 2026-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-01-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
NCT05262257
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
NCT04304261
Cognitive Functions and BDNF in T2DM and Prediabetes Patients
NCT05654727
Diabetes and Cognitive Functions in Middle Age
NCT05919927
Early Detection of Cognitive Dysfunction in Diabetes
NCT01830998
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SGLT2 inhibitors and DPP4 inhibitors are antidiabetic medications, have shown promise not only in glycemic control but also in potentially mitigating cognitive decline and depressive symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SGLT2 I Group
T2DM patients given SGLT2 Is + metformin added to standard of care
SGLT2 Is+METFORMIN
Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months
DPP4I group
T2DM patients given DPP4Is + metformin added to standard of care
DPP4 Is+metformin
Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months
Control group
T2DM patients given conventional therapy only
Control group
patients administered their standard of care without any changes for the past 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGLT2 Is+METFORMIN
Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months
DPP4 Is+metformin
Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months
Control group
patients administered their standard of care without any changes for the past 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. T2DM adult subjects (\>55 years old) will be eligible to participate.
2. Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.
Exclusion Criteria
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Abdelfattah Elsayed
Lecturer of clinical pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni Suef Hospital
Banī Suwayf, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeniSuef University Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.